FIELD: medicine; oncology.
SUBSTANCE: invention can be used to determine the risk of developing hematogenic metastasis in the patients with non-small cell lung cancer (NSCLC) after the radical surgical treatment. Method involves determining the expression level of genes in tumor tissue and histologically unchanged lung tissue using specific primers for mRNA of five actin-binding proteins (ACP): cyclase-associated protein adenylate 1, cofilin 1, profilin 1, fascin 1 and ezrin, then performing a comparative analysis of the level of mRNA expression coding genes of the five listed actin-binding proteins in the tumor tissue relative to the histologically unchanged lung tissue, wherein the increase in the mRNA expression level of each ACS in the tumor tissue as compared to the unchanged patient is evaluated as 1 point, and the total score of 3 to 5 shows an increased risk of developing hematogenous metastases.
EFFECT: use of the invention enables higher accuracy, information value of metastatic disease risk prediction, reduced analysis time.
1 cl, 4 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF DEVELOPMENT OF PROGRESSION IN A LONG PERIOD IN PATIENTS WITH SQUARE CELL CANCER OF THE HEAD AND NECK | 2021 |
|
RU2765013C1 |
| METHOD FOR PREDICTION OF RISK OF DEVELOPING DISTANT METASTASES IN PATIENTS WITH OPERABLE FORMS OF BREAST CANCER WITH METASTASES IN REGIONAL LYMPH NODES | 2020 |
|
RU2733697C1 |
| METHOD FOR EVALUATING THE DEGREE OF RISK OF ADVERSE EVALUATION OF DISEASE IN PATIENTS WITH GASTRIC CANCER | 2016 |
|
RU2662085C1 |
| METHOD FOR PREDICTING FIVE-YEAR NONMETASTATIC SURVIVAL IN BREAST CANCER PATIENTS BASED ON THE EXPRESSION OF THE YKL-39 AND CCL18 PROTEIN GENES | 2017 |
|
RU2659676C1 |
| METHOD FOR PREDICTION OF ONSET OF HEMATOGENOUS METASTASES ACCOMPANYING SQUAMOUS CELL LUNG CANCER | 2012 |
|
RU2489718C1 |
| METHOD FOR PREDICTING THE OUTCOME OF A DISEASE IN PATIENTS WITH LUMINAL AND THRICE NEGATIVE BREAST CANCER IN PATIENTS WHO DID NOT RECEIVE CHEMOTHERAPY OR HORMONE THERAPY IN THE NEOADJUVANT REGIMEN | 2017 |
|
RU2648523C1 |
| METHOD OF FORECASTING PERSONSIVE SURVIVABILITY IN PATIENTS WITH BREAST CANCER | 2016 |
|
RU2623869C1 |
| METHOD FOR PREDICTING THE DEGREE OF RISK OF DEVELOPING HEMATOGENOUS METASTASES IN INVASIVE CARCINOMA OF A NON-SPECIFIC TYPE OF MAMMARY GLAND BASED ON THE ASSESSMENT OF THE EXPRESSION OF LIMCH1 PROTEIN | 2020 |
|
RU2755242C1 |
| METHOD FOR PREDICTION OF DEVELOPING HAEMATOGENOUS METASTASES FOLLOWING COMBINED TREATMENT OF KIDNEY CANCER | 2013 |
|
RU2528100C1 |
| METHOD FOR PREDICTING RISK OF LYMPHATIC CANCER SPREAD IN BREAST CANCER BASED ON YKL-39 PROTEIN GENE EXPRESSION | 2016 |
|
RU2632115C1 |
